WuXi Biologics (Cayman) Inc.

Equities

2269

KYG970081173

Biotechnology & Medical Research

Market Closed - Hong Kong S.E. Other stock markets 04:08:34 2024-07-17 EDT			5-day change	1st Jan Change
11.28 ^HKD	+2.17%		+5.82%	-61.89%

06-27	Bank of China Downgrades Wuxi Biologics (Cayman) to Hold From Buy, Price Target is HK$14	MT
06-19	Wuxi Biologics Terms US Plant's Expansion Halt as Normal Business Adjustment	MT

WuXi Biologics signs exclusive deal with GSK

January 05, 2023 at 04:06 am

WuXi Biologics Inc - China-based contract research, development & manufacturing organisation, offering end-to-end biologics solutions - Enters into a license deal with GSK PLC for one preclinical bi-specific T cell engaging antibody and the option of three additional bi- & multi-specific TCE antibodies developed using WuXi Biologics' proprietary technology platforms. Says WuXi Biologics will get an upfront payment of USD40 million and tiered royalties on net sales.

WuXi Biologics Chief Executive Officer Chris Chen says: "We are looking forward to enabling GSK to bring these potentially life-saving therapeutics to more patients worldwide."

WuXi Biologics current stock price: HKD67.50

12-month change: down 14%

GSK current stock price: 1,427.60 pence, down 1.4% on Thursday morning in London

12-month change: down 12%

By Xindi Wei, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Stocks mentioned in the article

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
	GSK PLC	1,528 GBX	+1.83%	+1.56%	79.3B
	WUXI BIOLOGICS (CAYMAN) INC.	11.28 HKD	+2.17%	+5.82%	5.87B

Latest news about WuXi Biologics (Cayman) Inc.

Bank of China Downgrades Wuxi Biologics (Cayman) to Hold From Buy, Price Target is HK$14	06-27	MT
Wuxi Biologics Terms US Plant's Expansion Halt as Normal Business Adjustment	06-19	MT
WuXi Biologics Surges to 19-Month High Wednesday on Hopes of Avoiding US Ban	06-13	MT
US lawmakers ask FBI for briefing on GenScript Biotech's links to China	06-01	RE
US lawmakers ask FBI for briefing on GenScript Biotech's links to China	05-31	RE
China stocks rise as industrial profits grow; energy, semiconductor shares lead gains	05-27	RE
Wuxi Biologics (Cayman) Maintains it is Not a Security Threat After House Bill Changes; Stocks Drop 3%	05-17	MT
US House committee advances bill to restrict BGI, WuXi AppTec	05-15	RE
US House committee to vote on bill to restrict BGI, WuXi AppTec	05-15	RE
US Congress Drafts Bill Asking Drug Firms to Unlink from Chinese Biotech Firms	05-14	MT
WuXi Shares Volatile as U.S. Bill Revised to Set Deadline for Decoupling	05-13	DJ
U.S. bill to restrict WuXi AppTec, other Chinese biotech cos revised to give more time to cut ties	05-10	RE
Pacific Assets Trust cautiously optimistic after outpacing benchmark	04-30	AN
Wuxi Biologics Inc. Announces Retirement of Weichang Zhou as Chief Technology Officer and President of Global Biologics Development and Operations and Re-Designates as Non-Executive Director and Honorary President of Global Biologics Development and Operations and Senior Advisor to Chief Executive Officer	04-01	CI
WuXi Biologics' 2023 Profit Falls 23% Despite Revenue Jump	03-27	MT
WuXi Biologics 2023 Net Profit Fell on Higher Expenses, Impairment Losses	03-26	DJ
WuXi Biologics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-26	CI
Hong Kong Shares Slip Amid Downbeat Earnings, Cautious Trade	03-19	MT
WuXi AppTec's Shares Fall After Downbeat Guidance	03-19	DJ
WuXi AppTec's Net Profit Jumps, Reiterates It Doesn't Pose Security Threat	03-18	DJ
WuXi Biologics Inc.(SEHK:2269) dropped from S&P International 700	03-17	CI
WuXi Biologics Inc.(SEHK:2269) dropped from S&P Global 1200	03-17	CI
Hong Kong Shares Drop as PBoC Keeps Key Policy Rate Unchanged	03-15	MT
WuXi Shares Fall as Washington Lobbying Group Cuts Ties	03-14	DJ
China stocks steady, helped by biotech rally; Wuxi Apptec drags Hong Kong shares	03-14	RE

Chart WuXi Biologics (Cayman) Inc.

Duration

Period

More charts

Company Profile

WuXi Biologics (Cayman) Inc is an investment holding company principally engaged in the provision of end-to-end solutions and services for biologics discovery, development and manufacturing to customers involving in biologics industry. The Company mainly operates its business through two segments. The Biologics segment mainly engages in the provision of biologics discovery, development and manufacturing. The WuXi XDC (XDC) segment mainly engages in the provision of contract research, development and manufacturing organization (CRDMO) services for antibody-drug conjugate (ADCs) and various bioconjugates. The Company mainly conducts its business in the domestic and overseas markets.

Sector

Biotechnology & Medical Research

Calendar

2024-08-18 - Q2 2024 Earnings Release (Projected)

Related indices

HONG KONG HANG SENG

More about the company

Income Statement Evolution

More financial data

Ratings for WuXi Biologics (Cayman) Inc.

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

10.49 CNY

Average target price

20.93 CNY

Spread / Average Target

+99.52%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
WUXI BIOLOGICS (CAYMAN) INC.	-61.89%	5.87B
VERTEX PHARMACEUTICALS INCORPORATED	+20.03%	126B
REGENERON PHARMACEUTICALS, INC.	+23.61%	118B
ARGENX SE	+23.26%	27.87B
BIONTECH SE	-18.07%	20.95B
GENMAB A/S	-15.13%	16.92B
BEIGENE, LTD.	-14.81%	16.18B
NEUROCRINE BIOSCIENCES, INC.	+9.78%	14.84B
WUXI APPTEC CO., LTD.	-46.10%	14.79B
SAREPTA THERAPEUTICS, INC.	+52.34%	14.08B

Bio Therapeutic Drugs